|
Asthma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy.
|
31779161 |
2019 |
|
IgE-mediated food allergy
|
0.030 |
Biomarker
|
disease |
BEFREE |
Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy.
|
31779161 |
2019 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> HRF is efficacious and safe for the treatment of GBM.
|
31681570 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Malignant neoplasm of gallbladder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Gallbladder Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Stage 0 Gallbladder Cancer AJCC v8
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Stage IIA Gallbladder Cancer AJCC v8
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Stage IIB Gallbladder Cancer AJCC v8
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Stage III Gallbladder Cancer AJCC v8
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Stage IV Gallbladder Cancer AJCC v8
|
0.020 |
Biomarker
|
disease |
BEFREE |
Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.
|
31481102 |
2019 |
|
Polycystic Ovary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-204 suppresses cell proliferation and promotes apoptosis in ovarian granulosa cells via targeting TPT1 in polycystic ovary syndrome.
|
31460785 |
2019 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCTP could be considered as a candidate therapeutic target to prevent DOX-induced heart failure.
|
31320615 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
TCTP could be considered as a candidate therapeutic target to prevent DOX-induced heart failure.
|
31320615 |
2019 |
|
Chronic urticaria
|
0.020 |
Biomarker
|
disease |
BEFREE |
Dimerized, Not Monomeric, Translationally Controlled Tumor Protein Induces Basophil Activation and Mast Cell Degranulation in Chronic Urticaria.
|
31281717 |
2019 |
|
Chronic idiopathic urticaria
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TCTP levels were higher in patients with severe CSU (p=0.049) and with IgG positivity to FcɛRIα (p=0.038).
|
31281717 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, these results supported the fact that green tea contained potential compounds with an ability to inhibit the cancer by disrupting the co-chaperon p23 activity.
|
31257629 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hence, these results supported the fact that green tea contained potential compounds with an ability to inhibit the cancer by disrupting the co-chaperon p23 activity.
|
31257629 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Active Fraction from Embryo Fish Extracts Induces Reversion of the Malignant Invasive Phenotype in Breast Cancer through Down-regulation of TCTP and Modulation of E-cadherin/β-catenin Pathway.
|
31052313 |
2019 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Active Fraction from Embryo Fish Extracts Induces Reversion of the Malignant Invasive Phenotype in Breast Cancer through Down-regulation of TCTP and Modulation of E-cadherin/β-catenin Pathway.
|
31052313 |
2019 |
|
Hormone refractory prostate cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our previous study also found that AIL targets p23 against castration-resistant prostate cancer.
|
31048010 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggested that TPT1-AS1 induced EOC tumor growth and metastasis through TPT1 and downstream PI3K/AKT signaling and that TPT1-AS1 may be a promising therapeutic target for EOC.
|
30941821 |
2019 |
|
Carcinogenesis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression.
|
30941821 |
2019 |
|
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggested that TPT1-AS1 induced EOC tumor growth and metastasis through TPT1 and downstream PI3K/AKT signaling and that TPT1-AS1 may be a promising therapeutic target for EOC.
|
30941821 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results suggested that TPT1-AS1 induced EOC tumor growth and metastasis through TPT1 and downstream PI3K/AKT signaling and that TPT1-AS1 may be a promising therapeutic target for EOC.
|
30941821 |
2019 |